Back to top
more

INC Research Holdings, Inc. (SYNH)

(Delayed Data from NSDQ)

$47.27 USD

47.27
483,054

+0.56 (1.20%)

Updated May 3, 2019 04:00 PM ET

After-Market: $47.36 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Syneos Health (SYNH) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Syneos Health (SYNH) delivered earnings and revenue surprises of 9.68% and 2.05%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syneos Health Launches Initiative for COVID-19 Patients

by Zacks Equity Research

The primary aim of this initiative by Syneos Health (SYNH) is to address the predicted ventilator deficiency in the wake of the coronavirus pandemic.

Syneos Health (SYNH) Down 49.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Syneos Health Grows on New Alliances Amid Regulatory Upheavals

by Zacks Equity Research

Syneos Health's (SYNH) new partnerships with AiCure and Indegene Omnipresence seem strategic at the moment.

    Here's Why You Should Hold Syneos Health in Your Portfolio Now

    by Zacks Equity Research

    Syneos Health (SYNH) enjoys high investor confidence on solid prospects.

      Syneos Health (SYNH) Tops Q4 Earnings and Revenue Estimates

      by Zacks Equity Research

      We are upbeat about the strong year-over-year revenue growth in the Clinical Solutions segment of Syneos Health (SYNH) in Q4.

      Urmimala Biswas headshot

      5 Best Value Picks to Grab on Discounted PEG

      by Urmimala Biswas

      Value investors with varied risk appetite are unlikely to consider price/earnings to growth (PEG) ratio among a number of other popular metrics.

      Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?

      by Zacks Equity Research

      Syneos Health (SYNH) gains from several positive developments.

      SYNH vs. HMSY: Which Stock Should Value Investors Buy Now?

      by Zacks Equity Research

      SYNH vs. HMSY: Which Stock Is the Better Value Option?

      Is Syneos Health (SYNH) a Great Value Stock Right Now?

      by Zacks Equity Research

      Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

      Syneos Health Collaborates with AiCure for Patient Engagement

      by Zacks Equity Research

      Syneos Health (SYNH) aims to optimize patient engagement and trial success by partnering with AiCure.

        3 Reasons Why Growth Investors Shouldn't Overlook Syneos Health (SYNH)

        by Zacks Equity Research

        Syneos Health (SYNH) could produce exceptional returns because of its solid growth attributes.

        SYNH vs. OMCL: Which Stock Should Value Investors Buy Now?

        by Zacks Equity Research

        SYNH vs. OMCL: Which Stock Is the Better Value Option?

        Syneos Health (SYNH) Tops Q3 Earnings Estimates, Ups EPS View

        by Zacks Equity Research

        Syneos Health (SYNH) exhibits robust topline performance in the third quarter, backed by strong segmental growth.

        Syneos Health (SYNH) Surpasses Q3 Earnings Estimates

        by Zacks Equity Research

        Syneos Health (SYNH) delivered earnings and revenue surprises of 4.82% and -0.44%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

        ResMed's (RMD) Q1 Earnings Beat Estimates, Margins Expand

        by Zacks Equity Research

        ResMed (RMD) registers growth at CER across its key operating segments in Q1.

        Integra LifeSciences' (IART) Earnings Top Estimates in Q3

        by Zacks Equity Research

        We are upbeat about the year-over-year revenue growth in Integra LifeSciences' (IART) Codman Specialty Surgical segment.

        Syneos Health (SYNH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

        by Zacks Equity Research

        Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

        Edwards Lifesciences (EW) Beats on Q3 Earnings, Ups EPS View

        by Zacks Equity Research

        Edwards Lifesciences (EW) reports strong Q3 sales on the recent FDA indication expansion of SAPIEN 3 and SAPIEN 3 Ultra systems.

        Varian (VAR) Earnings and Revenues Surpass Estimates in Q4

        by Zacks Equity Research

        Varian (VAR) gains from core Oncology segment's solid contribution in fiscal Q4.

        Align Technology (ALGN) Beats on Q3 Earnings, Margins Fall

        by Zacks Equity Research

        We are upbeat about Align Technology (ALGN) witnessing continued momentum in Invisalign volumes across all geographies

        Boston Scientific (BSX) Beats on Q3 Earnings, Tapers EPS View

        by Zacks Equity Research

        Boston Scientific (BSX) is making an all-out effort to solidify its core businesses and invest in the new technologies as well as the global markets. This reflects on the sales uptick in Q3.

        Thermo Fisher (TMO) Beats on Q3 Earnings, Lifts Guidance

        by Zacks Equity Research

        We are encouraged that three out of Thermo Fisher's (TMO) four business segments have registered strong year-over-year revenue growth in Q3.

        SYNH vs. CERN: Which Stock Is the Better Value Option?

        by Zacks Equity Research

        SYNH vs. CERN: Which Stock Is the Better Value Option?